Vitiligo

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.

TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies that investigated ruxolinitib cream for the treatment of vitiligo over 52 weeks. We were delighted to speak to Dr. Amit G. Pandya (Palo Alto Foundation Medical Group, Sunnyvale, CA, USA) ...

Ruxolitinib cream, a cream formulation of the JAK 1/JAK2 inhibitor was first approved for use in vitiligo by the FDA in July 2022 and is the only topical treatment approved for repigmentation. We were delighted to speak to Dr. Amit G. ...

TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies investigating ruxolitinib cream in adults and adolescents with vitiligo. touchIMMUNOLOGY were delighted to speak with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the rationale and findings from his pooled analysis looking at the effect of ruxolitinib cream on achievement of VASI50 by body region. The abstract 'Effect of Ruxolitinib Cream on Achievement of VASI50 by Body Region: Week 52 Pooled Analysis of the TRuE-V Phase 3 Studies.' (Abstract number: 3640) was presented at EADV 2022, 7-10 September, 2022. Questions Could you give us a brief overview of the clinical development of ruxolitinib cream which has led to its approval for the treatment of vitiligo? (0:11) What have been the efficacy and safety findings of the TRuE-V studies, and how clinically meaningful are these findings? (0:52) What was the rationale for the pooled analysis you are presenting? (1:45) What were the findings of this analysis and what are the implications of these findings? (2:38) What has been the clinical impact of ruxolitinib cream in this indication since its approval? (3:27) Disclosures: Thierry Passeron discloses consulting for Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, and UCB pharma; receiving grant/ research support from Abbvie, Almirall, BMS, Celgene, Incyte, Isocell, LEO Pharma, and Lilly; and receiving honoraria from Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, and UCB pharma. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

It was a pleasure to speak with Prof. John E Harris (University of Massachusetts Medical School, Worcester, MA, USA) about the use of JAK inhibitors in vitiligo, what we have learned from their discontinuation and how this has helped drive the development of IL-15-targeted therapies. His presentation entitled ‘Vitiligo: from topical JAK inhibitors to anti-IL15R’ was given at the EADV 30th Congress, 29 Sep – 2 Oct 2021 Questions Could you tell us a little about current and emerging JAK inhibitors in the management of vitiligo? (0:12) What has been the impact of ruxolitinib on the treatment of vitiligo, and what is known about the effect of discontinuing treatment? (1:18) What have we learned about resident memory CD8 T cells and how might this cell subset be targeted in future therapeutic approaches? (2:29) Disclosures: Prof. John E Harris has acted as a consultant and investigator for Pfizer, Genzyme/ Sanofi, Incyte, Rheos Medicines, Sun Pharmaceutical, LEO Pharma, Villaris Therapeutics, Dermavant and TeVido BioDevices; a consultant for AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, NIRA Biosciences, Admirx, Granular Therapeutics and Platelet BioGenesis; has Equity in TeVido Biodevices, Rheos, Villaris Therapeutics, NIRA Biosciences and is Founder of Villaris Therapeutics and NIRA Biosciences. Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson. Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

As always, it was an honor to speak with Prof. John E Harris (University of Massachusetts Medical School, Worcester, MA, USA) about therapies, old and new, that have been used in the treatment of vitiligo. His presentation entitled ‘Vitiligo: from topical JAK inhibitors to anti-IL15R’ was given at the EADV 30th Congress, 29 Sep – 2 Oct 2021. Questions Could you give us a brief overview of vitiligo, its prevalence and its association with other autoimmune diseases? (0:12) How do newer treatments compare to traditional autoimmune therapies? (0:57) Disclosures: Prof. John E Harris has acted as a consultant and investigator for Pfizer, Genzyme/ Sanofi, Incyte, Rheos Medicines, Sun Pharmaceutical, LEO Pharma, Villaris Therapeutics, Dermavant and TeVido BioDevices; a consultant for AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, NIRA Biosciences, Admirx, Granular Therapeutics and Platelet BioGenesis; has Equity in TeVido Biodevices, Rheos, Villaris Therapeutics, NIRA Biosciences and is Founder of Villaris Therapeutics and NIRA Biosciences. Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickleson. Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.